[go: up one dir, main page]

MX2023010737A - Nuevo agente de contraste para utilizar en imagenes por resonancia magnetica. - Google Patents

Nuevo agente de contraste para utilizar en imagenes por resonancia magnetica.

Info

Publication number
MX2023010737A
MX2023010737A MX2023010737A MX2023010737A MX2023010737A MX 2023010737 A MX2023010737 A MX 2023010737A MX 2023010737 A MX2023010737 A MX 2023010737A MX 2023010737 A MX2023010737 A MX 2023010737A MX 2023010737 A MX2023010737 A MX 2023010737A
Authority
MX
Mexico
Prior art keywords
magnetic resonance
contrast agent
resonance imaging
new contrast
compounds
Prior art date
Application number
MX2023010737A
Other languages
English (en)
Inventor
Markus Berger
Thomas Brumby
Jessica Lohrke
Olaf Panknin
Sven Wittrock
Simon Anthony Herbert
Gregor Jost
Hubertus Pietsch
Thomas Frenzel
Claudia Green
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2023010737A publication Critical patent/MX2023010737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con una nueva clase de compuestos de fórmula general (I), con los complejos de quelato de Gd3+ de los mismos, con métodos para preparar dichos compuestos, y con el uso de dichos compuestos como agentes de contraste para IRM.
MX2023010737A 2021-03-15 2022-03-14 Nuevo agente de contraste para utilizar en imagenes por resonancia magnetica. MX2023010737A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21162650.2A EP4059925A1 (en) 2021-03-15 2021-03-15 New contrast agent for use in magnetic resonance imaging
PCT/EP2022/056541 WO2022194777A1 (en) 2021-03-15 2022-03-14 New contrast agent for use in magnetic resonance imaging

Publications (1)

Publication Number Publication Date
MX2023010737A true MX2023010737A (es) 2023-09-20

Family

ID=74874752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010737A MX2023010737A (es) 2021-03-15 2022-03-14 Nuevo agente de contraste para utilizar en imagenes por resonancia magnetica.

Country Status (21)

Country Link
US (1) US20240182431A1 (es)
EP (2) EP4059925A1 (es)
JP (1) JP2024512459A (es)
KR (1) KR20230157412A (es)
CN (1) CN116981658A (es)
AR (1) AR126325A1 (es)
AU (1) AU2022236333A1 (es)
CA (1) CA3213386A1 (es)
CL (1) CL2023002723A1 (es)
CO (1) CO2023012137A2 (es)
CR (1) CR20230433A (es)
DO (1) DOP2023000185A (es)
EC (1) ECSP23070062A (es)
ES (1) ES3034297T3 (es)
GE (2) GEP20257722B (es)
IL (1) IL305294A (es)
MA (1) MA63787B1 (es)
MX (1) MX2023010737A (es)
PE (1) PE20240821A1 (es)
TW (1) TW202302543A (es)
WO (1) WO2022194777A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210069A1 (en) * 2022-01-11 2023-07-12 Bayer Aktiengesellschaft Synthetic contrast-enhanced ct images
WO2024046832A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046833A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046831A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
CN119816744B (zh) 2022-09-05 2025-09-26 拜耳公司 生成人工对比度增强的放射图像
EP4336204A1 (de) 2022-09-07 2024-03-13 Bayer AG Beschleunigen von mrt-untersuchungen der leber
EP4335462A1 (en) * 2022-09-09 2024-03-13 Bayer AG Contrast agents for use in diagnostic computed tomography imaging
WO2024083466A1 (de) 2022-10-17 2024-04-25 Bayer Aktiengesellschaft Automatisches analysieren von radiologischen aufnahmen
CN116444428A (zh) * 2022-10-25 2023-07-18 无锡贝塔医药科技有限公司 一种吡啶环3-位引入c-14标记的乙醇基团的方法
EP4369285A1 (de) 2022-11-12 2024-05-15 Bayer AG Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4369353A1 (de) 2022-11-12 2024-05-15 Bayer Aktiengesellschaft Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4375919A1 (de) 2022-11-25 2024-05-29 Bayer AG Erzeugen von kontrastverstärkten synthetischen radiologischen aufnahmen
EP4471710B1 (de) 2023-05-30 2025-12-17 Bayer Aktiengesellschaft Erkennen von artefakten in synthetischen medizinischen aufnahmen
EP4475137B1 (de) 2023-06-05 2025-12-03 Bayer Aktiengesellschaft Erzeugen von künstlichen kontrastverstärkten radiologischen aufnahmen
EP4485474A3 (de) 2023-06-05 2025-04-16 Bayer AG Erzeugen von künstlichen kontrastverstärkten radiologischen aufnahmen
EP4498324A1 (de) 2023-07-25 2025-01-29 Bayer AG Erkennen von artefakten in synthetischen bildern
EP4567716A1 (en) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Generating synthetic representations
EP4567715A1 (en) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Generating synthetic representations
EP4571650A1 (en) 2023-12-12 2025-06-18 Bayer AG Generating synthetic images
EP4618009A1 (en) 2024-03-15 2025-09-17 Bayer Aktiengesellschaft Generation of a synthetic medical image
WO2025190828A1 (en) 2024-03-15 2025-09-18 Bayer Aktiengesellschaft Correction of an mri image
WO2025190826A1 (en) 2024-03-15 2025-09-18 Bayer Aktiengesellschaft Generation of a synthetic medical image
EP4664393A1 (de) 2024-06-10 2025-12-17 Bayer Aktiengesellschaft Erzeugen von synthetischen kontrastverstärkten radiologischen aufnahmen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
DE3922005A1 (de) 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
GB9407435D0 (en) 1994-04-14 1994-06-08 Nycomed Salutar Inc Compounds
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
DE19507820A1 (de) * 1995-02-21 1996-08-22 Schering Ag Neuartig substituierte DTPA-Derivate, deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
IT1293778B1 (it) 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
WO2001082795A2 (en) 2000-05-04 2001-11-08 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10231799B4 (de) 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005033902B3 (de) 2005-07-15 2007-04-05 Schering Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
WO2013083535A1 (en) 2011-12-05 2013-06-13 Bracco Imaging Spa Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis
MX2021013055A (es) * 2019-04-26 2021-12-10 Five Eleven Pharma Inc Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.

Also Published As

Publication number Publication date
EP4059925A1 (en) 2022-09-21
EP4308551A1 (en) 2024-01-24
EP4308551B1 (en) 2025-04-09
WO2022194777A1 (en) 2022-09-22
GEP20257722B (en) 2025-01-27
BR112023017197A2 (pt) 2023-09-26
IL305294A (en) 2023-10-01
CO2023012137A2 (es) 2023-09-29
DOP2023000185A (es) 2023-10-15
TW202302543A (zh) 2023-01-16
JP2024512459A (ja) 2024-03-19
CL2023002723A1 (es) 2024-01-26
KR20230157412A (ko) 2023-11-16
AR126325A1 (es) 2023-10-04
ECSP23070062A (es) 2023-10-31
CN116981658A (zh) 2023-10-31
ES3034297T3 (en) 2025-08-14
MA63787B1 (fr) 2025-07-31
AU2022236333A1 (en) 2023-08-31
US20240182431A1 (en) 2024-06-06
PE20240821A1 (es) 2024-04-18
EP4308551C0 (en) 2025-04-09
CA3213386A1 (en) 2022-09-22
GEAP202416374A (en) 2024-01-10
CR20230433A (es) 2023-10-23

Similar Documents

Publication Publication Date Title
MX2023010737A (es) Nuevo agente de contraste para utilizar en imagenes por resonancia magnetica.
JP5513405B2 (ja) 自己磁性金属サレン錯体化合物
MX374249B (es) Nuevos compuestos de quelato de gadolinio para usar en imágenes de resonancia magnética.
EP4473980A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
ATE218554T1 (de) Hepatobillianische magnetische resonanz- kontrastmittel
RU2017116176A (ru) Конъюгированные бисфосфонаты для диагностики и терапии заболеваний костей
RU2013125778A (ru) Cest-системы, проявляющие не зависящую от концентрации чувствительность
JPH04500964A (ja) キレート組成物
JP2018523671A5 (es)
JP2012167067A (ja) 自己磁性金属サレン錯体化合物
RU2018145061A (ru) Хелатные соединения
EP3551614A1 (en) Dimeric contrast agents
TNSN08016A1 (en) Complexes containing perfluoroalkyl, method for the production and use thereof
MX2024015341A (es) Derivados de 1,4-bis-(2-hidroxi-bencil)-1,4,7-triazaciclononano y compuestos similares como ligandos en complejos de hierro(iii) para su uso como agentes de contraste de resonancia magnetica
IL108433A0 (en) Dtpa metal complex derivatives, pharmaceutical compositions containing the same, and methods for the preparation thereof
RU2019118365A (ru) Хелатные соединения марганца на основе тетраазабицикло-макроцикла, подходящие в качестве визуализирующих агентов для MRI
BR112022003242A2 (pt) Composto, composição, e, métodos de formação de imagens, de síntese enantiosseletiva e de produção
PH12019502882A1 (en) Nanoparticle, contrast agent for magnetic resonance imaging containing same, and ligand compound
CA2482327A1 (en) Pendant fatty acid imaging agents
PH12021551522A1 (en) Nanoparticle, contrast agent for magnetic resonance imaging comprising same and zwitterionic ligand compound
Zhang et al. Synthesis neutral rare earth complexes of diethylenetriamine-N, N ″-bis (acetyl-isoniazid)-N, N′, N ″-triacetic acid as potential contrast enhancement agents for magnetic resonance imaging
WO2002026267A3 (en) Manganes complexes for magnetic resonance imaging
NZ787150A (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
TW200606172A (en) Galactopyrannosyltriaminetetracarboxylate as ligands for bio-activated paramagnetic metal complexes
TH2101003774A (th) อนุภาคนาโน, สารให้ความต่างชัดสำหรับการสร้างภาพเรโซแนนซ์แม่เหล็ก ที่ประกอบรวมด้วย สิ่งเดียวกันนั้นและสารประกอบสวิตเตอไอออนิกลิแกนด์